argenx SE (ARGX) Stock Score, Valuation & Financial Research
argenx SE is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 62/100.
Quick answer for ARGX
argenx SE currently has a Wall Street Score of 62/100. The stored market price is $979.76. Its financial score is 72/100. Its valuation score is 68/100. The latest WSS change is +0.9 points. These figures are a research snapshot, not a buy or sell recommendation.
What argenx SE does
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive dev
ARGX financial snapshot
- Wall Street Score:
- 62/100
- Current price:
- $979.76
- Market capitalization:
- $60.93B
- Revenue:
- $7.54B
- Net income:
- $2.22B
- Free cash flow:
- $844.3M
- Cash:
- $3.58B
- Total debt:
- $47.0M
- EPS:
- 36.11
- P/E ratio:
- 27.1x
- Financial score:
- 72/100
- Valuation score:
- 68/100
- Revenue score:
- 57/100
What stands out
- Reported year-over-year revenue growth is +0.8%.
- Free cash flow is $844.3M, showing positive cash generation.
- The balance sheet shows $3.58B of cash versus $47.0M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.9 points: ARGX increased 0.9 points because Valuation improved by 9.2 points.
What the numbers mean
Its current valuation score is 68/100, which Wall Street Score classifies as mixed within the model's valuation framework.
The financial score is 72/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ARGX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.